Immunohistochemical expression of HER2/neu in colorectal carcinoma in Erbil city, Kurdistan Region
Background and objective: Colorectal carcinoma is one of the commonest cancers and the second leading cause of cancer death in Europe and North America. Despite the improved surgeries and adjuvant therapies, the prognosis of colorectal cancer remains poor, and the survival rate is unsatisfactory. Overexpression of HER2 gene has been noticed in many human cancers, and it is associated with poor prognosis. This study aimed to detect the frequency of the HER2/neu immunoexpression in colorectal carcinoma and investigate its association with the clinicopathological parameters.
Methods: A retrospective study was carried out in Rizgary teaching hospital and private laboratories in Erbil city for the period from January 2014 - December 2017. A total of 103 formalin fixed, paraffin embedded, archival tissue blocks of colectomy samples of colorectal carcinoma cases were collected. Immunostaining was done in a private laboratory (Vin Lab) in Dohuk city. Scoring of the HER2/neu immunostaining was managed according to published criteria for breast carcinoma.
Results: Fifty-five cases (53.4%) were labeled as positive for HER2/neuimmunoexpression. While 48 (46.6%) of the cases were labeled as negative. HER2/neu status was significantly associated with the tumor grade (P = 0.02), while no significant association was found between HER2/neu expression and other clinicopathological parameters.
Conclusion: HER2/neu immunoexpression was observed in 53.4% of the cases of colorectal carcinoma, and it was significantly associated with tumor grade.
Ingold HB, Behrens H-M, Balschun K, Haag J, Krüger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014; 111(10):1977–84.
Abdulghafour KH. Immunohistochemical Expression of Her2 / Neu Receptor in Human Colorectal Carcinoma (A Clinicopathological Study). IASJ 2014; 13(3):424–9.
Roseweir AK, McMillan DC, Horgan PG, Edwards J. Colorectal cancer subtypes: Translation to routine clinical pathology. Cancer Treat Rev 2017; 57:1–7.
Sun S-J, Lin Q, Sun Q, Li J, Zhang X-Y, Tan Z-G, et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J Cancer Res Ther 2016; 12(1):323.
Sayadnejad N, Firouzjahi A, Shafaee S, Golshahi H, Sokouti Z. Immunohistochemical study of HER2 / neu expression in colorectal cancer and its relation to other clinicopathological criteria and prognostic factors. Int J Cancer Manag 2017; 10(5):e5700.
Wu S, Ma C, Li W. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis. Diagn Pathol 2015; 10(1):144.
Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002; 99(3):1521–6.
Li S, Buchbinder E, Wu L, Bjorge JD, Fujita DJ, Zhu S. EGFR and HER2 levels are frequently elevated in colon cancer cells. Discoveries 2014; 1(1):1–8.
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of reviews ERBB receptors and cancer. Nat Rev Cancer 2005; 354:341–54.
Hynes NE, Macdonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21:177–84.
Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, et al. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer 2015; 112(1):103.
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. Colon and Rectum. In: J Milburn Jessup, Richard MG, Elliot AA, AB Benson III, James DB, George JC, eds. AJCC Cancer Staging Manual. 8th ed. Chicago: Springer Nuture; 2017. P. 251–74.
Nathanson DR, Culliford AT, Shia J, Chen B, D’Alessio M, Zeng Z-S, et al. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003; 105(6):796–802.
Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, Kim WH, et al. HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 2014; 9(5):e98528.
Varga Z, Noske A. Impact of modified 2013 ASCO/CAP guidelines on HER2 testing in breast cancer. one year experience. PLoS One 2015; 10(10):e0140652.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52(7):797–805.
Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 2010; 251(5):896–901.
De Simone V, Pallone F, Monteleone G, Stolfi C. Role of T H 17 cytokines in the control of colorectal cancer. Oncoimmunology 2013; 2(12):e26617.
Suma S, Ummerali SK. HER2 / neu expression in colorectal cancers. IJCMR 2017; 4(6):1240–3.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11):783–92.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3):719–26.
Park D Il, Kang MS, Oh SJ. HER-2 / neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007; 22(5):491–7.
Kavanagh DO, Chambers G, O’Grady L, Barry KM, Waldron RP, Bennani F, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009; 9:1.
Pappas A, Lagoudianakis E, Seretis C, Tsiambas E, Koronakis N, Toutouzas K, et al. Clinical role of HER-2/neu expression in colorectal cancer. J BUON 2013;18(1):98–104.
Tu J, Yu Y, Liu W, Chen S. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med 2015; 9(1):17–24.
Meng X, Huang Z, Di J, Mu D, Wang Y, Zhao X, et al. Expression of human epidermal growth factor receptor-2 in resected rectal cancer. Med 2015; 94(47):e2106.
Torabizadeh Z, Nosrati A, Tahvildari S. Human epidermal growth factor receptor expression in colorectal cancer and its relationship with clinicopathological characteristics. Middle East J Dig Dis 2015; 8(1):24–30.
Mohammadi G, Jamialahma K, Lary S, Ghaffarzad K. Expression of membranous epidermal growth factor receptor in colorectal adenocarcinoma and it’s correlation with clinicopathological features. Pakistan J Biol Sci 2011; 14(5):357–62.
Karaca H, Deniz K, Berk V, Inanc M, Ozkan M. Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer. Asian Pac J Cancer Prev 2012; 13(12):6221–5.
Madani SH, Sadeghi E, Rezaee A, Sadeghi M, Khazaee S, Amirifard N, et al. Survey of HER2-neu expression in colonic adenocarcinoma in the West of Iran. Asian Pacific J Cancer Prev 2015;16(17):7671–4.
Shabbir A, Mirza T, Khalid AB, Qureshi MA, Asim SA. Frequency of Her2/neu expression in colorectal adenocarcinoma: A study from developing South Asian Country. BMC Cancer 2016; 16(1):855.
Lu M, Hu K. Correlation of HER2 and FOXM1 in human colorectal carcinoma and its clinical significance. Int J Clin Exp Pathol 2017; 10(12):11624–34.
Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2 / neu and VEGF expression in colon carcinomas. BMC Cancer 2011; 11(1):277.
Molaei M, Pejhan S, Nayer BN, Moradi A, Ghiasi S, Zali MR. Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: Correlation with survival and clinicopathological findings. Eur J Gastroenterol Hepatol 2009; 21(3):289–93.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).